Sugammadex - Merck

While the rest of Merck's pipeline has been refocused and driven forward, sugammadex remains mired in regulatory woes at the FDA.

What's wrong with sugammadex? Plenty, evidently. Earlier this year the FDA capped 7 years of discussions and setbacks with its third straight rejection.

Regulators have never been satisfied with the hypersensitivity study that was done for the application, requiring more site inspections. And that forced the FDA to cancel another advisory committee review and spurn the latest application.

Merck ($MRK) has consistently maintained that this program is one of their crown jewels in the pipeline, even gaining R&D chief Roger Perlmutter's endorsement after he joined the pharma giant. But the drug has instead tended to highlight the old Merck's unending R&D woes prior to Perlmutter's arrival.

For more:
FDA bats down Merck's sugammadex in third rejection
Merck can't get the sugammadex curse lifted, faces 3rd FDA rejection
Merck R&D hammered by another setback as FDA rejects anesthesia drug (again)

Sugammadex - Merck
Read more on

Suggested Articles

A phase 3 study of NuCana’s lead drug was halted because a monitoring committee deemed it unlikely to succeed.

The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.

The Allen Institute found major differences in human and mouse brain cells, which could guide the design of drugs for brain diseases.